Literature DB >> 1335664

Risk of hepatitis A in travellers.

R Steffen1.   

Abstract

A review of the literature shows that 30-35 million travellers from industrialized nations annually visit a developing country where their incidence rate of symptomatic hepatitis A is 3 to 6 per 1000 per month of stay if they remain unprotected. The risk is 20 per 1000 for persons eating and drinking under poor hygienic conditions. Thus hepatitis A is now the most frequent vaccine-preventable disease in such travellers. Antibodies to hepatitis A virus are rarely found in potential travellers in many industrialized countries, except in those born before 1944, in those with a history of jaundice, or in those with a stay > 1 year in a developing country.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335664     DOI: 10.1016/0264-410x(92)90548-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Protecting travellers from hepatitis A.

Authors:  G Webster; E Barnes; G Dusheiko; I Franklin
Journal:  BMJ       Date:  2001-05-19

2.  Hepatitis A in urban Ireland.

Authors:  E Rajan; B O'Farrell; A G Shattock; J F Fielding
Journal:  Ir J Med Sci       Date:  1998 Oct-Dec       Impact factor: 1.568

3.  Immunizations for international travelers.

Authors:  W T Thanassi
Journal:  West J Med       Date:  1998-03

4.  New combined hepatitis A and B vaccine. Risks Of viral hepatitis related to travel.

Authors:  J N Zuckerman
Journal:  BMJ       Date:  1998-04-25

Review 5.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

6.  Virological course of hepatitis A virus as determined by real time RT-PCR: Correlation with biochemical, immunological and genotypic profiles.

Authors:  Zahid Hussain; Bhudev C Das; Syed A Husain; Sunil K Polipalli; Tanzeel Ahmed; Nargis Begum; Subhash Medhi; Alice Verghese; Mohammad Raish; Apiradee Theamboonlers; Yong Poovorawan; Premashis Kar
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

7.  Cost effectiveness of hepatitis A prevention in France.

Authors:  C A Severo; F Fagnani; A Lafuma
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 8.  Infectious diseases.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  1994-02       Impact factor: 2.401

Review 9.  Safety and effectiveness of the new inactivated hepatitis A virus vaccine.

Authors:  J Furesz; D W Scheifele; L Palkonyay
Journal:  CMAJ       Date:  1995-02-01       Impact factor: 8.262

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.